Skip to main content

A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TA

Submitted by Josh on Mon, 02/05/2024 - 16:41
  • Read more about A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TA

A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (IMbrave152)

Submitted by Josh on Mon, 02/05/2024 - 16:41
  • Read more about A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (IMbrave152)

DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors

Submitted by Josh on Mon, 02/05/2024 - 16:41
  • Read more about DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors

A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases

Submitted by Josh on Mon, 02/05/2024 - 16:41
  • Read more about A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases

ALT-FLOW II Trial of the Edwards APTURE Transcatheter Shunt System

Submitted by Josh on Mon, 02/05/2024 - 16:41
  • Read more about ALT-FLOW II Trial of the Edwards APTURE Transcatheter Shunt System

A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

Submitted by Josh on Mon, 02/05/2024 - 16:41
  • Read more about A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations

Submitted by rachel on Wed, 01/17/2024 - 15:52
  • Read more about Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Submitted by rachel on Wed, 01/17/2024 - 15:52
  • Read more about Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

Submitted by rachel on Wed, 01/17/2024 - 15:52
  • Read more about A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs

Submitted by rachel on Wed, 01/17/2024 - 15:51
  • Read more about Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 22
  • Page 23
  • Page 24
  • Page 25
  • Page 26
  • Page 27
  • Page 28
  • Page 29
  • Page 30
  • …
  • Next page Next
  • Last page Last
Subscribe to